摘要
目的:评价乌拉地尔与其它血管扩张剂治疗急性左心衰竭的疗效。方法:80例急性左心衰竭患者随机分为4组:乌拉地尔组(19例)、酚妥拉明组(21例)、硝普钠组(16例)和硝酸甘油组(24例),观察记录治疗前后的呼吸困难、心率、血压及肺部罗音的变化。结果:乌拉地尔组和硝普钠组对呼吸困难缓解率分别为94.7%和93.8%(P>0.05),硝酸甘油组为47.7%(P<0.01);酚妥拉明组心率增快发生率为66.7%,乌拉地尔组为5.3%(P<0.01)。硝普钠组血压下降和低血压发生率为31.3%,乌拉地尔组为5.3%(P<0.05);乌拉地尔组和酚妥拉明组减少肺部罗音有效率分别为94.7%和95.2%(P>0.05),硝酸甘油组为58.3%(P<0.05)。结论:乌拉地尔可以作为救治急性左心衰竭的首选药物之一。
Objective：To evaluate the clinical efficacy between urapidil and other vasodilators in acute left heart failure. Methods： 80 patients with acute left heart failure were randomly divided into 4 groups： urapidil group （n = 19 ） , phentolamine group （n =21 ）, sodium nitroprusside group （ n = 16）, nitroglycerin group （ n = 24 ）, The change of dyspneic respiration, heart rate, blood preasure, and lung rales were recorded respectively in the process of the treatment. Results ： Remission rate of dyspnea were 94.7% and 93.8% in urapidil group and sodium nitroprusside group respectively （ P 〉 0.05 ） , nitroglycerin group was 47.7% （ P 〈 0. 01 ）, Incidence of heart rate acceleration were 66.7% and 5.3% in phentolamine group and urapidil group respectively （ P 〈0. 01 ）, Incidence of blood pressure lowering and hypotension were 31.3% and 5.3% in sodium nitroprusside group and urapidil group respectively （P 〈0. 05 ）. Effective rate of reducing lung tales were 94.7% and 95. 2% respectively （P 〉 0.05 ） , nitroglycerin group was 58. 3% （P 〈 0.05 ）, Conclusion：The result proved that urapidil could be used as first aid for patients with acute left heart failure.
出处
《药学实践杂志》
CAS
2007年第5期297-299,共3页
Journal of Pharmaceutical Practice
